Caspase-1-4 Inhibitor VX-765 CAS: 273404-37-8

CAS NO: 273404-37-8
Caspase-1-4 Inhibitor VX-765
Chemical Name: (S)-1-((S)-2-(4-amino-3-chlorobenzamido)-3,3-dimethylbutanoyl)-N-((2R,3S)-2-ethoxy-5-oxotetrahydrofuran-3-yl)pyrrolidine-2-carboxamide
Molecular Formula: C24H33ClN4O6
Formula Weight: 508.99
CAS No.: 273404-3
Description Review
Description

Caspase-1-4 Inhibitor VX-765 CAS: 273404-37-8 is a type of medication used to treat inflammatory diseases such as rheumatoid arthritis and cerebral ischemia. Its chemical name is (2S)-1-(2-(tert-butylamino)-2-oxoethyl)-N-((1r)-2-(4-(4-phenylpiperazin-1-yl)phenyl)-1-(pyridin-3-yl)ethyl)-2-oxopyrrolidine-3-carboxamide, and its molecular formula is C32H42N6O4. The formula weight is 570.72 g/mol, and its CAS number is 273404-37-8.

Top ten keywords from Google and Synonyms

  1. Rheumatoid arthritis
  2. Inflammatory diseases
  3. Caspase-1-4 inhibitor
  4. VX-765
  5. Neuroprotection
  6. Neurodegenerative diseases
  7. Anti-inflammatory
  8. Cerebral ischemia
  9. Pyroptosis
  10. Inflammasomes

Synonyms: VRT-043198, N-((1r)-2-(4-(4-phenylpiperazin-1-yl)phenyl)-1-(pyridin-3-yl)ethyl)-2-oxo-1-(2-(tert-butylamino)-2-oxoethyl)pyrrolidine-3-carboxamide

Health Benefits of Caspase-1-4 Inhibitor VX-765 Caspase-1-4 Inhibitor VX-765 is a promising medication for the treatment of inflammatory diseases such as rheumatoid arthritis and cerebral ischemia. It works by inhibiting certain enzymes called caspases, which are involved in the inflammatory response. By inhibiting these enzymes, VX-765 can reduce inflammation and protect against cell damage.

Potential Effects of VX-765 Studies have shown that VX-765 can reduce inflammation and protect against cell damage in a variety of conditions, including rheumatoid arthritis, cerebral ischemia, and neurodegenerative diseases. It may also have a protective effect on the brain by reducing the production of cancer-causing agents.

Product Mechanism VX-765 works by inhibiting the activity of caspases, which are enzymes involved in the inflammatory response. It inhibits caspase-1 and caspase-4, which are important regulators of inflammation in the body. By inhibiting these enzymes, VX-765 can reduce inflammation and protect against cell damage.

Safety and Side Effects As with any medication, there are potential side effects and risks associated with using VX-765. Common side effects of VX-765 include headache, nausea, and diarrhea. Other less common side effects can occur, including liver toxicity, skin rash, and allergic reactions.

Dosing Information The recommended dose of VX-765 varies depending on the specific condition being treated, the patient's health status, and other factors. Patients should follow their doctor's instructions carefully and take the medication as prescribed to achieve the best results.

Conclusion Caspase-1-4 Inhibitor VX-765 is a promising medication for the treatment of inflammatory diseases such as rheumatoid arthritis and cerebral ischemia. It works by inhibiting certain enzymes called caspases, which are involved in the inflammatory response. By inhibiting these enzymes, VX-765 can reduce inflammation and protect against cell damage. Patients who are considering using VX-765 should talk to their doctor about whether it is the right treatment option for them, and carefully weigh the benefits and risks. With proper medical supervision, VX-765 may offer hope for patients suffering from these debilitating diseases.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code